Ariad submits EU MAA for ponatinib and prepares to storm Europe
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. Tim Clackson, the firm's CSO and president of R&D, explained how Ariad will makes it name in the European oncology market and why partnering is not the way to do it.
You may also be interested in...
USCMA Revision Worsens Innovator Woes In Canada
Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
What’s Next After 20 Years Of NICE?
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Need a specific report? 1000+ reports available
Buy Reports